Abstract 3253
Background
Peptide receptor radionuclide therapy (PRRT) with 177Lutetium (177Lu) -DOTATATE is effective treatment for neuroendocrine tumors (NETs). Dosimetry assessment can be used to maximize the tumour dose, while keeping the dose delivered to critical organs to acceptable levels. The association between tumour absorbed dosimetry (TAD) and progression-free (PFS) and overall survival (OS) is not well understood.
Methods
Single institution retrospective analysis of patients with metastatic NET whom underwent up to 4 cycles of 7.45GBq 177Lu octreotate PRRT. Intra-therapeutic tumour dosimetry was performed with non-gated single photon emission computed tomography (SPECT) to quantify activity at 5 time points after administration of 177 Lu during cycle 1. TAD per injected activity (A0) and estimated total TAD (multiplied by total administered activity of 177Lu) was correlated with OS and PFS using the Kaplan–Meier method and Cox proportional-hazards model.
Results
79 patients were included, primary site: gastroenteric (48%), pancreatic (39%), bronchial (9%), other (4%), ECOG Performance status (PS) 0/1 (94%), Grade: G1 (47%), G2 (42%), G3 (11%), Ki-67≤20% (89%), concurrent chemotherapy use (29%). Mean TAD/A0 was 9(7-11) Gy/GBq. Progressive disease (54%) and death (29%) was seen. Median follow-up of 35 months. Median PFS was 32 [26-38] months. PFS was shorter with increasing ECOG PS (P = 0.02), tumour grade (P < 0.01), Ki-67 (P = 0.01), concurrent chemo-radionuclide therapy (P = 0.02) and reduced TAD (P = 0.036) but not primary site of origin (P = 0.66). A higher TAD led to an improved median PFS in pancreatic (P < 0.01) versus gastroenteric (P = 0.56) NETs. In a multivariate model incorporating ECOG PS, Ki-67 and chemotherapy use, total TAD remained significantly associated with PFS. The mean OS was 40 [36-44] months. OS was shorter with increasing tumour grade (P = 0.05), Ki-67 (P = 0.036) and reduced TAD (P = 0.039).
Conclusions
TAD was independently associated with OS and PFS validating dosimetry assessment in NET patients undergoing PRRT. Prospective refinement of the association on larger, more homogenous cohorts of NET patients is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Presenter: Louise Rasmussen
Session: Poster Display session 2
Resources:
Abstract
5124 - STAR_PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer.
Presenter: Hemant Kocher
Session: Poster Display session 2
Resources:
Abstract
5257 - Outcomes of First Line FOLFIRINOX (FFX) Versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience
Presenter: Neha Papneja
Session: Poster Display session 2
Resources:
Abstract
1166 - Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1169 - Association of combination of irreversible electroporation ablation and chemotherapy with outcomes of locally advanced pancreatic cancer: a large cohort study
Presenter: Chaobin He
Session: Poster Display session 2
Resources:
Abstract
1222 - Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer
Presenter: Yusuke Hashimoto
Session: Poster Display session 2
Resources:
Abstract
1698 - Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer
Presenter: Masato Ozaka
Session: Poster Display session 2
Resources:
Abstract
2424 - Irinotecan Combined with Oxaliplatin and S1 in Patients with Metastatic Pancreatic Adenocarcinoma
Presenter: Keke Nie
Session: Poster Display session 2
Resources:
Abstract
2885 - Cancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study
Presenter: Satoshi Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3702 - A Phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-Paclitaxel in patients with advanced pancreatic cancer
Presenter: Muhammad Beg
Session: Poster Display session 2
Resources:
Abstract